Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics.

With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options.

In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like.

• 01:22 Meet Daniel Vitt
• 04:54 Understanding multiple sclerosis
• 07:53 Evolution of the MS treatment landscape
• 12:08 Immunic’s lead MS therapy explained
• 22:57 World MS Day and what's next for Immunic

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• 11 neuroscience biotech companies you should know about
• The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval
• Six biotech companies advancing multiple sclerosis therapies

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.

00:55: The challenges of liver disease

04:44: How Lexogen supports NGS drug discovery

07:29: Major transcriptomics developments

10:05: Designing high quality AI data

15:47: How the Ochre-Lexogen partnership began

17:17: Why a specialist partner is essential for scale

18:21: Lexogen delivers on the massive sequencing project

21:50: Why high quality data is crucial

27:02: Lexogen's role in AI discovery

34:51: Future plans and directions

This episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• Deep phenotyping brings accuracy to precision medicine
• Spatial Transcriptomics: A window into disease
• Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions

Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled.

My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark.

• 01:07 Meet Dominic Clarke and Cryoport Systems
• 06:24 Fresh cells versus frozen cells
• 08:21 Why teams switch to cryopreservation late
• 12:37 The challenge of variability
• 16:47 IntegriCell when you already have a process in place
• 22:17 An argument for cryopreservation based on data
• 25:56 The future of IntegriCell and Cryoport Systems

This episode is brought to you with the support of Cryoport Systems.

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• IntegriCell® Cryopreservation
• Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience
• Cracking the code: Delivering biotherapeutics successfully across EMEA

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. Ryan's journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021.

We'll explore the frustrations of fragmented lab tools that inspired Lab Thread's integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We’ll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs.

I hope you enjoy Ryan’s insights on evolving digital workflows and accelerating breakthroughs in the lab.

01:51: Meet Ryan Cawood

02:31: Frustrations with early digital tools.

03:19: Daily lab organization challenges.

06:50: Time lost to admin tasks.

11:09: Genesis of the Lab Thread concept.

13:53: Integrated workflow functionality explained.

17:23: Enhancing experiment reproducibility methods.

20:37: Achieving compliance standards easily.

26:10: The future of digital lab management.

28:33: Accelerating scientific breakthroughs.

This episode is brought to you with the support of Lab Thread.

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• Lab Thread - Your Lab, Connected
• Hiding in plain sight: how to solve bioscience’s software problem
• Lab chaos and digital dreams

This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr.

Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.

In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions.

• 01:43 Meet Stanley Qi
• 03:32 Founding Epicrispr
• 05:53 CRISPR interference and epigenome explained
• 10:04 Overview of GEMS gene modulation system
• 11:28 Reversibility and safety of epigenetic edits
• 18:42 Strategy for tackling multiple disease conditions
• 23:27 Clinical trial plans for EPI-321 candidate
• 30:06 Looking forward

This episode is brought to you with the support of MedChemExpress.

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• Could CRISPR really cure these diseases?
• 10 gene therapy companies you should know about
• CRISPR technology’s next wave: Ten companies to watch

Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics.

A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms.

In this episode, Patrick walks us through his personal journey into science, the company’s DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal’s oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond.

• 01:33 Meet Patrick Andre
• 08:01 Diagonal’s mission
• 11:39 What are clustering antibodies
• 16:05 Receptor clustering benefits for HHT and PAH
• 20:24 Preclinical data on preventing and reversing HHT pathology
• 22:39 The impact of the $125 Million Series B financing round

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• Vaderis emerges from stealth to start HHT trial
• Pulmonary hypertension after Winrevair: where GSK’s $950M bet fits
• New treatment for pulmonary hypertension: what biotech holds in store?

Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in pharma R&D, then as co-founder of Kurma Partners, and now leading Argobio’s unique venture-builder model.

Since raising €50 million in 2021, Argobio has co-founded and accelerated several companies from top European academic labs. Three of them—Enodia, Laigo Bio, and Elkedonia—have already closed seed rounds totaling more than €43 million, advancing novel platforms in targeted protein degradation, precision membrane protein degraders, and non-hallucinogenic neuroplasticity enhancers for depression.

Thierry shares how Argobio reduces execution risk, embeds operational expertise, and turns promising science into investable companies that can compete worldwide.

• 04:02 Blending pharmacology expertise with business
• 07:50 Vision behind starting Kurma Partners
• 12:53 Launching Argobio to address gaps in European biotech
• 17:40 What makes the Argobio operational venture builder model unique
• 25:02 Criteria for selecting academic scientific breakthroughs
• 27:34 Changing dynamics of commercializing European research
• 35:30 Europe vs US biotech investment climates
• 37:47 Role of venture studios in Europe’s biotech future

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• M Ventures: pharma CVC and biotech innovation in 2026
• Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giants
• Venture capital co-creation: The next big thing in biotech investment?

Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data.

Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics, a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery.

Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single-cell annotation. In a world abounding in AI hype, Parashar helps us cut through the noise and point out paths to data driven success.

• 01:00 Meet Parashar Dhapola
• 05:45 AI in biopharma
• 09:29 AI automation vs. new capabilities
• 11:28 What makes single-cell omics data different
• 18:46 Risks of incorrect cell annotation
• 34:37 Future of single-cell analytics

This episode is produced with the support of Nygen Analytics. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• CyteType - AI powered cell type annotation
• Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure?
• The past, present, and future of genome sequencing